Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
Nizar J Bahlis, Rachid Baz, Simon J Harrison, Hang Quach, Shir-Jing Ho, Annette Juul Vangsted, Torben Plesner, Philippe Moreau, Simon D Gibbs, Sheryl Coppola, Xiaoqing Yang, Abdullah Al Masud, Jeremy A Ross, Orlando Bueno, Jonathan L Kaufman, Nizar J Bahlis, Rachid Baz, Simon J Harrison, Hang Quach, Shir-Jing Ho, Annette Juul Vangsted, Torben Plesner, Philippe Moreau, Simon D Gibbs, Sheryl Coppola, Xiaoqing Yang, Abdullah Al Masud, Jeremy A Ross, Orlando Bueno, Jonathan L Kaufman
Abstract
Purpose: Venetoclax is an oral BCL-2 inhibitor with single-agent activity in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14) translocation. Venetoclax efficacy in RRMM may be potentiated through combination with agents including bortezomib, dexamethasone, and daratumumab.
Methods: This phase I study (NCT03314181) evaluated venetoclax with daratumumab and dexamethasone (VenDd) in patients with t(11;14) RRMM and VenDd with bortezomib (VenDVd) in cytogenetically unselected patients with RRMM. Primary objectives included expansion-phase dosing, safety, and overall response rate. Secondary objectives included further safety analysis, progression-free survival, duration of response, time to progression, and minimal residual disease negativity.
Results: Forty-eight patients were enrolled, 24 each in parts 1 (VenDd) and 2 (VenDVd). There was one dose-limiting toxicity in part 1 (grade 3 febrile neutropenia, 800 mg VenDd). Common adverse events with VenDd and VenDVd included diarrhea (63% and 54%) and nausea (50% and 50%); grade ≥ 3 adverse events were observed in 88% in the VenDd group and 71% in the VenDVd group. One treatment-emergent death occurred in part 2 (sepsis) in the context of progressive disease, with no other infection-related deaths on study with medians of 20.9 and 20.4 months of follow-up in parts 1 and 2, respectively. The overall response rate was 96% with VenDd (all very good partial response or better [≥ VGPR]) and 92% with VenDVd (79% ≥ VGPR). The 18-month progression-free survival rate was 90.5% (95% CI, 67.0 to 97.5) with VenDd and 66.7% (95% CI, 42.5 to 82.5) with VenDVd.
Conclusion: VenDd and VenDVd produced a high rate of deep and durable responses in patients with RRMM. These results support continued evaluation of venetoclax with daratumumab regimens to treat RRMM, particularly in those with t(11;14).
Conflict of interest statement
Nizar J. BahlisHonoraria: Celgene, Janssen, AbbVie, Amgen, Sanofi, Takeda, Karyopharm Therapeutics, GlaxoSmithKline, Genentech/RocheConsulting or Advisory Role: Janssen, Celgene, Amgen, Sanofi, Takeda, Pfizer, Karyopharm TherapeuticsResearch Funding: Janssen, Celgene Rachid BazConsulting or Advisory Role: Karyopharm Therapeutics, BMS, AbbVie, Oncopeptides, Shattuck Labs, SanofiResearch Funding: Karyopharm Therapeutics, Celgene, Merck Sharp & Dohme, Takeda, Signal Genetics, AbbVie, Sanofi, Janssen, BMS Simon J. HarrisonHonoraria: AbbVie, Amgen, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Janssen Cilag, Novartis, Roche/Genentech, Takeda, Haemalogix, SanofiConsulting or Advisory Role: AbbVie, Amgen, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Janssen Cilag, Novartis, Roche/Genentech, Takeda, Haemalogix, SanofiSpeakers' Bureau: AbbVie, Amgen, Celgene/Bristol Myers Squibb, GlaxoSmithKline, Janssen Cilag, Novartis, Roche/Genentech, Takeda, TerumoResearch Funding: Haemalogix, Janssen CilagExpert Testimony: EUSA Pharma, Terumo Hang QuachConsulting or Advisory Role: GlaxoSmithKline, Celgene, Karyopharm Therapeutics, Janssen-Cilag, CSL Behring, Amgen, SanofiResearch Funding: Celgene, Amgen, Karopharm, GlaxoSmithKline, Sanofi Torben PlesnerConsulting or Advisory Role: Janssen, Celgene, Takeda, AbbVie, Genmab, Oncopeptides, GenentechSpeakers' Bureau: Janssen, TakedaResearch Funding: Janssen, Genmab, Celgene, Takeda, Oncopeptides, Genentech, AbbVie, Roche Philippe MoreauHonoraria: Celgene, Janssen-Cilag, Amgen, GlaxoSmithKline, AbbVie, SanofiConsulting or Advisory Role: Celgene, Janssen, Amgen, GlaxoSmithKline, Sanofi, AbbVie Simon D. GibbsHonoraria: Janssen Oncology, Pfizer, AbbVie, Celgene/Bristol Myers Squibb, AmgenConsulting or Advisory Role: AbbVie Abdullah Al MasudEmployment: AbbVieStock and Other Ownership Interests: AbbVie Jeremy A. RossEmployment: AbbVieStock and Other Ownership Interests: AbbVie Orlando BuenoEmployment: AbbVieStock and Other Ownership Interests: AbbVieResearch Funding: AbbVieTravel, Accommodations, Expenses: AbbVie Jonathan L. KaufmanHonoraria: TecnofarmaConsulting or Advisory Role: Janssen, Celgene, TG Therapeutics, Sanofi, Tecnofarma, GenentechResearch Funding: Merck, Celgene, Janssen, Sutro Biopharma, Fortis, Amgen, AbbVie/Genentech, Bristol Myers SquibbTravel, Accommodations, Expenses: Janssen, Celgene, Bristol Myers Squibb, Sanofi, Amgen, TakedaNo other potential conflicts of interest were reported.
Figures
References
- Kumar SK, Lee JH, Lahuerta JJ, et al. : Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 26:149-157, 2012
- Majithia N, Rajkumar SV, Lacy MQ, et al. : Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia 30:2208-2213, 2016
- Ravi P, Kumar SK, Cerhan JR, et al. : Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 8:26, 2018
- San-Miguel JF, Mateos MV: Can multiple myeloma become a curable disease? Haematologica 96:1246-1248, 2011
- Bolli N, Avet-Loiseau H, Wedge DC, et al. : Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997, 2014
- Bolli N, Maura F, Minvielle S, et al. : Genomic patterns of progression in smoldering multiple myeloma. Nat Commun 9:3363, 2018
- Dutta AK, Fink JL, Grady JP, et al. : Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia 33:457-468, 2019
- Merz M, Hielscher T, Schult D, et al. : Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma. Leukemia 34:1192-1196, 2020
- Slomp A, Peperzak V: Role and regulation of pro-survival BCL-2 proteins in multiple myeloma. Front Oncol 8:533, 2018
- Reed JC: Bcl-2-family proteins and hematologic malignancies: History and future prospects. Blood 111:3322-3330, 2008
- Touzeau C, Ryan J, Guerriero J, et al. : BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 30:761-764, 2016
- Wu J, Ross J, Peale FV, Jr, et al. : A favorable BCL-2 family expression profile may explain the increased susceptibility of the t(11;14) multiple myeloma subgroup to single agent venetoclax. Blood 128, 2016. (abstr 5613)
- Gomez-Bougie P, Maiga S, Tessoulin B, et al. : BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood 132:2656-2669, 2018
- Kumar S, Kaufman JL, Gasparetto C, et al. : Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 130:2401-2409, 2017
- Silva AS, Renatino-Canevarolo R, Meads MB, et al. : Ex vivo drug sensitivity and functional genomics platform identifies novel combinations targeting intrinsic and extrinsic apoptotic signaling pathways in multiple myeloma. Blood 136:49-50, 2020
- Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, et al. : Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67:5418-5424, 2007
- Matulis SM, Gupta VA, Nooka AK, et al. : Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia 30:1086-1093, 2016
- Punnoose EA, Leverson JD, Peale F, et al. : Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther 15:1132-1144, 2016
- Moreau P, Chanan-Khan A, Roberts AW, et al. : Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood 130:2392-2400, 2017
- Corre J, Cleynen A, Robiou du Pont S, et al. : Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia 32:2636-2647, 2018
- van de Donk N, Usmani SZ: CD38 antibodies in multiple myeloma: Mechanisms of action and modes of resistance. Front Immunol 9:2134, 2018
- Kohlhapp FJ, Haribhai D, Mathew R, et al. : Venetoclax increases intra-tumoral effector T cells and anti-tumor efficacy in combination with immune checkpoint blockade. Cancer Discov 11:68-79, 2021
- Durie BG, Harousseau JL, Miguel JS, et al. : International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006. [Erratum: Leukemia 21:1134, 2007]
- Rajkumar SV, Harousseau JL, Durie B, et al. : Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 117:4691-4695, 2011
- Lonial S, Weiss BM, Usmani SZ, et al. : Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet 387:1551-1560, 2016
- Dimopoulos M, Quach H, Mateos MV, et al. : Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study. Lancet 396:186-197, 2020
- Palumbo A, Chanan-Khan A, Weisel K, et al. : Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375:754-766, 2016
- Ludwig H, Delforge M, Facon T, et al. : Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network. Leukemia 32:1542-1560, 2018
- Dimopoulos MA, Oriol A, Nahi H, et al. : Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375:1319-1331, 2016
- Facon T, Kumar S, Plesner T, et al. : Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380:2104-2115, 2019
- Kumar SK, Harrison SJ, Cavo M, et al. : Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21:1630-1642, 2020
- Bahlis NJ, Dimopoulos MA, White DJ, et al. : Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 34:1875-1884, 2020
- Weisel K, Spencer A, Lentzsch S, et al. : Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk. J Hematol Oncol 13:115, 2020
- Lokhorst HM, Plesner T, Laubach JP, et al. : Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373:1207-1219, 2015
- Usmani SZ, Weiss BM, Plesner T, et al. : Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood 128:37-44, 2016
- Kaufman JL, Gasparetto C, Schjesvold FH, et al. : Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. Am J Hematol 96:418-427, 2020
- Matulis SM, Gupta VA, Neri P, et al. : Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia 33:1291-1296, 2019
- Touzeau C, Dousset C, Le Gouill S, et al. : The Bcl-2 specific BH3 mimetic ABT-199: A promising targeted therapy for t(11;14) multiple myeloma. Leukemia 28:210-212, 2014
- Touzeau C, Maciag P, Amiot M, et al. : Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia 32:1899-1907, 2018
- Harrison S, Cavo M, De La Rubia J, et al. : T(11;14) and high BCL2 expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma: Biomarker analyses from the phase 3 BELLINI study. Blood 134, 2019. (abstr 142)
Source: PubMed